Jade Biosciences, Inc.(JBIO)

Biotechnology · Waltham, MA

$13.44-0.63 (-4.48%)

Delayed quote: Oct 6, 2026, 10:25 AM EDT

Price/OCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/OCF ratio is N/A as of 2026-10-06T14:26:58.795Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:26:58.795Z.

Quote observation: 2026-10-06T14:25:03.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 817,920,164
TTM operating cash flow · period ending 2026-06-30: -123,510,000

FMP input reference: 7de7752a9f7c92cf302168b3adc2b8952dbd3ee015c15fa7e623ade4200d4f53

P/E Ratio|P/FCF Ratio|Operating Cash Flow|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

JBIO Price/OCF Ratio Metrics

PRICE/OCF RATIO

N/A

JBIO Competitors' Price/OCF Ratio

JBIO

Jade Biosciences, Inc.

Current

Market Cap

$817.92M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

APMD

Apnimed, Inc.

vs JBIO

Market Cap

$818.83M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALMS

Alumis Inc.

vs JBIO

Market Cap

$825.62M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ARDX

Ardelyx, Inc.

vs JBIO

Market Cap

$809.02M

Price/OCF Ratio

N/A

TTM Avg

5.49

3Y Avg

6.61

5Y Avg

6.61

INMD

InMode Ltd.

vs JBIO

Market Cap

$808.81M

Price/OCF Ratio

9.13

TTM Avg

9.81

3Y Avg

9.87

5Y Avg

15.02

BBNX

Beta Bionics, Inc.

vs JBIO

Market Cap

$835.01M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AHCO

AdaptHealth Corp.

vs JBIO

Market Cap

$793.88M

Price/OCF Ratio

1.36

TTM Avg

2.23

3Y Avg

2.49

5Y Avg

4.68

GLUE

Monte Rosa Therapeutics, Inc.

vs JBIO

Market Cap

$843.53M

Price/OCF Ratio

N/A

TTM Avg

10.75

3Y Avg

10.75

5Y Avg

10.75

GYRE

Gyre Therapeutics, Inc.

vs JBIO

Market Cap

$791.01M

Price/OCF Ratio

N/A

TTM Avg

422.02

3Y Avg

258.29

5Y Avg

228.94

CRVS

Corvus Pharmaceuticals, Inc.

vs JBIO

Market Cap

$865.29M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Jade Biosciences, Inc. (JBIO)	$817.92M	N/A	N/A	N/A	N/A
Apnimed, Inc. (APMD)vs ›	$818.83M	N/A	N/A	N/A	N/A
Alumis Inc. (ALMS)vs ›	$825.62M	N/A	N/A	N/A	N/A
Ardelyx, Inc. (ARDX)vs ›	$809.02M	N/A	5.49	6.61	6.61
InMode Ltd. (INMD)vs ›	$808.81M	9.13	9.81	9.87	15.02
Beta Bionics, Inc. (BBNX)vs ›	$835.01M	N/A	N/A	N/A	N/A
AdaptHealth Corp. (AHCO)vs ›	$793.88M	1.36	2.23	2.49	4.68
Monte Rosa Therapeutics, Inc. (GLUE)vs ›	$843.53M	N/A	10.75	10.75	10.75
Gyre Therapeutics, Inc. (GYRE)vs ›	$791.01M	N/A	422.02	258.29	228.94
Corvus Pharmaceuticals, Inc. (CRVS)vs ›	$865.29M	N/A	N/A	N/A	N/A

Operating Cash Flow Valuation

P/OCF Ratio

N/A

P/FCF Ratio

N/A

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Price/OCF Ratio: N/A

JBIO Price/OCF Ratio Metrics

JBIO Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics